Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
  BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 8, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting research on the company’s pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October 15 to October 19, 2019 in
View HTML
Toggle Summary ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
  MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum     BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 2, 2019--   ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC ( M iransertib in
View HTML
Toggle Summary ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019
  BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare Conference on Thursday,
View HTML
Toggle Summary ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 17, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit Focused on Specialty
View HTML
Toggle Summary ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 28, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Marc Schegerin , Chief Financial Officer, will attend Citi’s investor conference on Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston,
View HTML
Toggle Summary ArQule Reports Second Quarter 2019 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 7, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2019. For the quarter ended June 30, 2019 , the Company reported a net loss of $9.1 million , or $0.08 per
View HTML
Toggle Summary ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- ArQule, Inc. (Nasdaq:ARQL) today announced that Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St.
View HTML
Toggle Summary ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at the SVB Leerink Spotlight Series: Rare &
View HTML
Toggle Summary ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 24, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 27, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.